RecruitingNCT06649097

Clearance of Intracranial Blood Products by Continuous Irrigation With the IRRAflow System


Sponsor

Christopher P Kellner

Enrollment

250 participants

Start Date

Sep 25, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The study is a multi-center prospective cohort, controlled, phase 4 post-market registry evaluating the efficacy and radiographic outcomes associated with the use of the IRRAflow® Active Fluid Exchange System compared to standard of care external ventricular drains.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Age \>=18 years of age
  • Intracranial hemorrhage documented on head CT or MRI scan.
  • Indication for active fluid exchange evaluated by treating physician.
  • Signed informed consent obtained by patient or Legal Authorized Representative
  • Scheduled enrollment and treatment within 72 hours of last known well (LKW)

Exclusion Criteria4

  • GCS ≤ 5
  • Pregnancy
  • Fixed and dilated pupil
  • Life-threatening medical condition

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEIRRAflow® CNS (Active Fluid Exchange) System

The IRRAflow system offers automated irrigation, controlled drainage and intracranial pressure (ICP) monitoring all in one system. It consists of three main parts - IRRAflow 2.0 Catheter, IRRAflow Tube Set, IRRAflow Control Unit.


Locations(1)

Icahn School of Medicine at Mount Sinai

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06649097


Related Trials